Connect your AI

Alkermes ALKS Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Jazz PharmaceuticalsJAZZ

——

Axsome TherapeuticsAXSM

——

Ionis PharmaceuticalsIONS

——

Halozyme TherapeuticsHALO

——

Other financials

Income statement

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alkermes's amortization of capitalized software and acquired intangible assets?: Alkermes (ALKS) reported amortization of capitalized software and acquired intangible assets of $11.68M in Q1 2026.
What is the long-term trend for Alkermes's amortization of capitalized software and acquired intangible assets?: Over 3 years (2021 to 2024), Alkermes's amortization of capitalized software and acquired intangible assets has grown at a -69.3% compound annual growth rate (CAGR), from $38.15M to $1.1M.